Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-positive Locally Advanced Unresectable”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Looking for participantsNCT06731478
What this trial is testing

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

Who this might be right for
Gastric CancerGastroesophageal Junction Cancer
Daiichi Sankyo 726
Large-scale testing (Phase 3)Active Not RecruitingNCT06238843
What this trial is testing

A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001)

Who this might be right for
Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Innovent Biologics (Suzhou) Co. Ltd. 464
Not applicableNot Yet RecruitingNCT07780968
What this trial is testing

Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA

Who this might be right for
Esophageal CancerGastroEsophageal CancerGastroesophageal-junction Cancer+2 more
Jazz Pharmaceuticals 300
Early research (Phase 1)Looking for participantsNCT07137416
What this trial is testing

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Invasive Breast Carcinoma+13 more
National Cancer Institute (NCI) 36
Testing effectiveness (Phase 2)Looking for participantsNCT04965766
What this trial is testing

Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerAdvanced Breast Cancer
Gustave Roussy, Cancer Campus, Grand Paris 139
Testing effectiveness (Phase 2)Study completedNCT04539938
What this trial is testing

Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer

Who this might be right for
HER2 Positive Breast Cancer
Seagen, a wholly owned subsidiary of Pfizer 70
Large-scale testing (Phase 3)Active Not RecruitingNCT04862663
What this trial is testing

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

Who this might be right for
Locally Advanced (Inoperable) or Metastatic Breast Cancer
AstraZeneca 893
Large-scale testing (Phase 3)UnknownNCT05755048
What this trial is testing

FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. 314
Testing effectiveness (Phase 2)Looking for participantsNCT07653685
What this trial is testing

A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.

Who this might be right for
Colorectal Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. 71
Not applicableAvailableNCT06048081
What this trial is testing

Early Access Program for Zolbetuximab

Who this might be right for
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma CancerLocally Advanced Unresectable Gastric Adenocarcinoma CancerMetastatic Gastric Adenocarcinoma Cancer+1 more
Astellas Pharma Global Development, Inc.
Testing effectiveness (Phase 2)Looking for participantsNCT06686394
What this trial is testing

Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)

Who this might be right for
Breast NeoplasmsBreast Cancer
Merck Sharp & Dohme LLC 81
Not applicableStudy completedNCT02393924
What this trial is testing

Human Epidermal Growth Factor Receptor 2 (HER2) Positive Unresectable Locally Advanced or Metastatic Breast Cancer Disease Registry Study

Who this might be right for
Breast Cancer
Hoffmann-La Roche 311
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07116824
What this trial is testing

HB1801 Combined Treatment of HER2-positive Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 80
Testing effectiveness (Phase 2)Ended earlyNCT01912963
What this trial is testing

Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer

Who this might be right for
HER2-positive Breast CancerMetastatic Breast Cancer
Dana-Farber Cancer Institute 32
Testing effectiveness (Phase 2)Looking for participantsNCT06767800
What this trial is testing

A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma

Who this might be right for
Gastroesophageal Adenocarcinoma
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. 204
Large-scale testing (Phase 3)Looking for participantsNCT07060807
What this trial is testing

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Who this might be right for
Breast Neoplasms
Merck Sharp & Dohme LLC 1,000
Early research (Phase 1)Looking for participantsNCT05098210
What this trial is testing

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Locally Advanced Cutaneous Melanoma+22 more
Fred Hutchinson Cancer Center 28
Testing effectiveness (Phase 2)UnknownNCT04839510
What this trial is testing

MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer

Who this might be right for
Locally Advanced Urothelial CancerMetastatic Urothelial Carcinoma
Shanghai Miracogen Inc. 58
Testing effectiveness (Phase 2)UnknownNCT05334810
What this trial is testing

DP303c in Patients With HER2-positive Unresectable Locally Advanced, Relapsed, or Metastaticbreast Cancer

Who this might be right for
HER2-positive Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 191
Testing effectiveness (Phase 2)Study completedNCT03112590
What this trial is testing

Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer

Who this might be right for
Breast CancerBreast Cancer, MaleBreast Cancer Female+1 more
H. Lee Moffitt Cancer Center and Research Institute 51
Next Page